Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, ...

Pfizer’s Albert Bourla put it more bluntly in Davos last month, saying it’s a “different world when you start discussing ...

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still ...

Big drug companies' pricing deals with the Trump administration barely came up during their most recent round of quarterly earnings calls, in yet another sign that the agreements were mutually ...

Pharma groups like $113 bln Sanofi and Pfizer have spent years investing in immunisations. But scepticism from the US ...

The whiplash over a new potential flu vaccine from Moderna, which went from rejected to approved for review in a matter of days, has illustrated a new reality plaguing the Cambridge biotech company ...

Thousands of lawsuits in the U.S. allege that the agrochemical maker Bayer failed to warn people that its popular weedkiller ...

Industry and US administration leaders lay out their plans to navigate a globally competitive pharma landscape with China’s growing dominance.

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...